User profiles for Manuel Battegay
 | Manuel BattegayUniversity of Basel, Switzerland Verified email at usb.ch Cited by 41184 |
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
BACKGROUND & AIMS: Hepatitis C virus (HCV) induces chronic infection in 50% to 80% of
infected persons; approximately 50% of these do not respond to therapy. We performed a …
infected persons; approximately 50% of these do not respond to therapy. We performed a …
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Background The efficacy of highly active antiretroviral therapy (HAART) in suppression of
HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in …
HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in …
[HTML][HTML] Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy …
…, M Stratmann, O Caviezel, M Stoeckle, M Battegay… - The Lancet, 2019 - thelancet.com
Background The level of evidence for HIV transmission risk through condomless sex in
serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral …
serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral …
COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation
Switzerland is among the countries with the highest number of coronavirus disease-2019 (COVID-19)
cases per capita in the world. There are likely many people with undetected SARS-…
cases per capita in the world. There are likely many people with undetected SARS-…
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study
…, B Ledergerber, H Furrer, M Battegay… - Clinical infectious …, 2011 - academic.oup.com
… Manuel Battegay , Manuel Battegay … The members of the Swiss HIV Cohort Study are as
follows: Barth J, Battegay M, Bernasconi E, Böni J, Bucher HC, Bürgisser P, Burton-Jeangros C, …
follows: Barth J, Battegay M, Bernasconi E, Böni J, Bucher HC, Bürgisser P, Burton-Jeangros C, …
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
…, M Rickenbach, R Malinverni, P Vernazza, M Battegay - Bmj, 1997 - bmj.com
Objectives: To examine trends in disease progression and survival among patients enrolled
in the Swiss HIV cohort study during 1988–96 and to assess the influence of new …
in the Swiss HIV cohort study during 1988–96 and to assess the influence of new …
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
…, V Erard, R Weber, B Hirschel, H Furrer, M Battegay… - Jama, 1999 - jamanetwork.com
ContextAcquired immunodeficiency syndrome–related opportunistic illnesses (OIs)
continue to occur after initiation of potent antiretroviral therapy in patients with human …
continue to occur after initiation of potent antiretroviral therapy in patients with human …
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
…, M Rickenbach, M Egger, M Battegay… - Archives of internal …, 2003 - jamanetwork.com
Background Highly active antiretroviral therapy (HAART) for human immunodeficiency virus
(HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-…
(HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-…
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24-or 96-well plates
M Battegay, S Cooper, A Althage, J Bänziger… - Journal of virological …, 1991 - Elsevier
Titers of lymphocytic choriomeningitis virus (LCMV) were determined on adherent fibroblast
cell lines in 24- or 96-well plates. After absorption of virus by cells and 48 h incubation under …
cell lines in 24- or 96-well plates. After absorption of virus by cells and 48 h incubation under …
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
…, B Ledergerber, E Bernasconi, H Furrer, M Battegay… - The Lancet, 2001 - thelancet.com
Background Data on adverse events to antiretroviral treatment have been recorded in
clinical trials, post-marketing analyses, and anecdotal reports. Such data might not be an up-to-…
clinical trials, post-marketing analyses, and anecdotal reports. Such data might not be an up-to-…